- Home
- MKZR vs SNSE Comparison
MKZR vs SNSE Comparison
Compare MKZR & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- SNSE
- Stock Information
- Founded
- MKZR 2012
- SNSE 2005
- Country
- MKZR United States
- SNSE United States
- Employees
- MKZR N/A
- SNSE N/A
- Industry
- MKZR
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- SNSE Health Care
- Exchange
- MKZR Nasdaq
- SNSE Nasdaq
- Market Cap
- MKZR 10.3M
- SNSE 10.8M
- IPO Year
- MKZR N/A
- SNSE 2021
- Fundamental
- Price
- MKZR $4.85
- SNSE $8.68
- Analyst Decision
- MKZR
- SNSE Strong Buy
- Analyst Count
- MKZR 0
- SNSE 4
- Target Price
- MKZR N/A
- SNSE $72.50
- AVG Volume (30 Days)
- MKZR 116.6K
- SNSE 33.8K
- Earning Date
- MKZR 08-26-2025
- SNSE 08-05-2025
- Dividend Yield
- MKZR 46.39%
- SNSE N/A
- EPS Growth
- MKZR N/A
- SNSE N/A
- EPS
- MKZR N/A
- SNSE N/A
- Revenue
- MKZR $23,037,348.00
- SNSE N/A
- Revenue This Year
- MKZR N/A
- SNSE N/A
- Revenue Next Year
- MKZR N/A
- SNSE N/A
- P/E Ratio
- MKZR N/A
- SNSE N/A
- Revenue Growth
- MKZR 52.64
- SNSE N/A
- 52 Week Low
- MKZR $3.89
- SNSE $5.00
- 52 Week High
- MKZR $55.00
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- SNSE 57.34
- Support Level
- MKZR N/A
- SNSE $7.34
- Resistance Level
- MKZR N/A
- SNSE $8.23
- Average True Range (ATR)
- MKZR 0.00
- SNSE 1.03
- MACD
- MKZR 0.00
- SNSE 0.03
- Stochastic Oscillator
- MKZR 0.00
- SNSE 50.48
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).